Keck School Faculty

Trevor Angell

Trevor Angell

Associate Professor of Clinical Medicine
Associate Medical Director of Thyroid Center
BMT B11 Off Campus Los Angeles

Malignancy Risk of Thyroid Nodules That Are Not Classifiable by the American Thyroid Association Ultrasound Risk Stratification System: A Systematic Review and Meta-Analysis Thyroid. 2023 Apr 13. . View in PubMed

Real World Performance of The Afirma Genomic Sequencing Classifier (GSC) - A Meta-analysis J Clin Endocrinol Metab. 2022 Dec 06. . View in PubMed

Performance of Thyroid-Stimulating Immunoglobulin Bioassay and Thyrotropin-Binding Inhibitory Immunoglobulin Assay for the Diagnosis of Graves' Disease in Patients With Active Thyrotoxicosis Endocr Pract. 2022 May; 28(5):502-508. . View in PubMed

Preoperative Identification of Medullary Thyroid Carcinoma (MTC): Clinical Validation of the Afirma MTC RNA-Sequencing Classifier Thyroid. 2022 09; 32(9):1069-1076. . View in PubMed

Factors Associated With Hospitalization Among Breast Cancer Patients With COVID-19: A Diverse Multi-Center Los Angeles Cohort Study Clin Breast Cancer. 2022 06; 22(4):e558-e566. . View in PubMed

Optimal Thyroid Hormone Replacement Dose in Immune Checkpoint Inhibitor-Associated Hypothyroidism Is Distinct from Hashimoto's Thyroiditis Thyroid. 2022 05; 32(5):496-504. . View in PubMed

Point of Care Measurement of Body Mass Index and Thyroid Nodule Malignancy Risk Assessment Front Endocrinol (Lausanne). 2022; 13:824226. . View in PubMed

Finding the Balance on Extent of Initial Thyroidectomy for Low-Risk Papillary Thyroid Carcinoma J Clin Endocrinol Metab. 2022 12 17; 108(1):e7-e8. . View in PubMed

Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy J Immunol. 2022 08 15; 209(4):696-709. . View in PubMed

COVID-19 Outcomes of Patients With Differentiated Thyroid Cancer: A Multicenter Los Angeles Cohort Study Endocr Pract. 2021 Feb; 27(2):90-94. . View in PubMed

Hypoglycemic episodes predict length of stay in patients with acute burns J Crit Care. 2021 08; 64:68-73. . View in PubMed

Hürthle cell lesions of the thyroid: Progress made and challenges remaining Cancer Cytopathol. 2021 05; 129(5):347-362. . View in PubMed

Extrapulmonary manifestations of severe acute respiratory syndrome coronavirus-2 infection J Med Virol. 2021 05; 93(5):2645-2653. . View in PubMed

Changes in Stage Distribution and Disease-Specific Survival in Differentiated Thyroid Cancer with Transition to American Joint Committee on Cancer 8th Edition: A Systematic Review and Meta-Analysis Oncologist. 2021 02; 26(2):e251-e260. . View in PubMed

Completion Thyroidectomy is Less Common Following Updated 2015 American Thyroid Association Guidelines Ann Surg Oncol. 2021 Jan; 28(1):484-491. . View in PubMed

Analysis of the strategy of LT4 prescribing and TSH monitoring for thyroid carcinoma after lobectomy Ann Transl Med. 2020 Oct; 8(19):1238. . View in PubMed

Letter to the Editor: Use of Molecular Diagnostic Tests in Thyroid Nodules with Hürthle Cell-Dominant Cytology Thyroid. 2020 09; 30(9):1390-1392. . View in PubMed

Insights From a Real-World Study of Molecular Test Performance for Indeterminate Thyroid Nodules J Clin Endocrinol Metab. 2020 04 01; 105(4). . View in PubMed

Treatment of Differentiated Thyroid Carcinomas Surg Pathol Clin. 2019 Dec; 12(4):931-942. . View in PubMed

Getting more out of molecular testing for indeterminate thyroid nodules Cancer Cytopathol. 2019 Sep; 127(9):555-556. . View in PubMed

The Impact of Hashimoto Thyroiditis on Thyroid Nodule Cytology and Risk of Thyroid Cancer J Endocr Soc. 2019 Apr 01; 3(4):791-800. . View in PubMed

Tall Cell Variant of Papillary Thyroid Carcinoma: Impact of Change in WHO Definition and Molecular Analysis Endocr Pathol. 2019 Mar; 30(1):43-48. . View in PubMed

Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate Thyroid Nodules Thyroid. 2019 11; 29(11):1594-1605. . View in PubMed


Thyroid Nodules and Thyroid Cancer in the Pregnant Woman Endocrinol Metab Clin North Am. 2019 09; 48(3):557-567. . View in PubMed

Differences in Thyroid Nodule Cytology and Malignancy Risk Between Children and Adults Thyroid. 2019 08; 29(8):1097-1104. . View in PubMed

The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders Cancer Immunol Res. 2019 07; 7(7):1214-1220. . View in PubMed

Independent Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules Thyroid. 2019 05; 29(5):650-656. . View in PubMed

Effect of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) on Malignancy Rates in Thyroid Nodules: How to Counsel Patients on Extent of Surgery Ann Surg Oncol. 2019 Jan; 26(1):93-97. . View in PubMed

Analytical and Clinical Validation of Expressed Variants and Fusions From the Whole Transcriptome of Thyroid FNA Samples Front Endocrinol (Lausanne). 2019; 10:612. . View in PubMed

A Cohort Analysis of Clinical and Ultrasound Variables Predicting Cancer Risk in 20,001 Consecutive Thyroid Nodules J Clin Endocrinol Metab. 2019 11 01; 104(11):5665-5672. . View in PubMed


Reasons Associated with Total Thyroidectomy as Initial Surgical Management of an Indeterminate Thyroid Nodule Ann Surg Oncol. 2018 May; 25(5):1410-1417. . View in PubMed

Unique Cytologic Features of Thyroiditis Caused by Immune Checkpoint Inhibitor Therapy for Malignant Melanoma Genes Dis. 2018 Mar; 5(1):46-48. . View in PubMed

Molecular Testing of Nodules with a Suspicious or Malignant Cytologic Diagnosis in the Setting of Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) Endocr Pathol. 2018 Mar; 29(1):68-74. . View in PubMed

Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers Thyroid. 2018 04; 28(4):445-453. . View in PubMed

Quantitative Analysis of the Benefits and Risk of Thyroid Nodule Evaluation in Patients =70 Years Old Thyroid. 2018 04; 28(4):465-471. . View in PubMed

Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients Thyroid. 2018 04; 28(4):437-444. . View in PubMed

Natural History and Outcomes of Cytologically Benign Thyroid Nodules in Children J Clin Endocrinol Metab. 2018 09 01; 103(9):3557-3565. . View in PubMed

Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules JAMA Surg. 2018 09 01; 153(9):817-824. . View in PubMed

A modified reporting approach for thyroid FNA in the NIFTP era: A 1-year institutional experience Cancer Cytopathol. 2017 Nov; 125(11):854-864. . View in PubMed

RAS-positive thyroid nodules Curr Opin Endocrinol Diabetes Obes. 2017 Oct; 24(5):372-376. . View in PubMed

The Flip Side of NIFTP: an Increase in Rates of Unfavorable Histologic Parameters in the Remainder of Papillary Thyroid Carcinomas Endocr Pathol. 2017 Jun; 28(2):171-176. . View in PubMed

Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes Cancer Cytopathol. 2017 05; 125(5):313-322. . View in PubMed

Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Accounts for More Than Half of "Carcinomas" Harboring RAS Mutations Thyroid. 2017 04; 27(4):506-511. . View in PubMed

Differential Growth Rates of Benign vsMalignant Thyroid Nodules. J Clin Endocrinol Metab. 2017 12 01; 102(12):4642-4647. . View in PubMed

Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent Thyroid. 2016 Mar; 26(3):381-9. . View in PubMed

Bethesda Categorization of Thyroid Nodule Cytology and Prediction of Thyroid Cancer Type and Prognosis Thyroid. 2016 Feb; 26(2):256-61. . View in PubMed

Long- versus short-interval follow-up of cytologically benign thyroid nodules: a prospective cohort study BMC Med. 2016 Jan 27; 14:11. . View in PubMed

Clinical, Sonographic, and Pathological Characteristics of RAS-Positive Versus BRAF-Positive Thyroid Carcinoma J Clin Endocrinol Metab. 2016 12; 101(12):4938-4944. . View in PubMed

Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier Thyroid. 2016 07; 26(7):911-5. . View in PubMed


The Influence of Patient Age on Thyroid Nodule Formation, Multinodularity, and Thyroid Cancer Risk J Clin Endocrinol Metab. 2015 Dec; 100(12):4434-40. . View in PubMed

Afirma Benign Thyroid Nodules Show Similar Growth to Cytologically Benign Nodules During Follow-Up J Clin Endocrinol Metab. 2015 Nov; 100(11):E1477-83. . View in PubMed

Localized LECT2 amyloidosis of the adrenal gland with coexisting MGUS: a diagnostic challenge Ann Hematol. 2015 Sep; 94(9):1603-4. . View in PubMed

The variable phenotype and low-risk nature of RAS-positive thyroid nodules BMC Med. 2015 Aug 07; 13:184. . View in PubMed

Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study J Clin Endocrinol Metab. 2015 Feb; 100(2):451-9. . View in PubMed

MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro Clin Cancer Res. 2014 Dec 01; 20(23):6034-44. . View in PubMed

BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration Thyroid. 2014 Sep; 24(9):1385-93. . View in PubMed

In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation Thyroid. 2014 Jul; 24(7):1127-33. . View in PubMed

Trevor E Angell, MD is an Assistant Professor of Clinical Medicine in the Department of Medicine’s Division of Endocrinology and Diabetes at Keck School of Medicine of USC. Dr. Angell is board certified in Internal Medicine and Endocrinology, Diabetes and Metabolism.
Dr. Angell is Associate Medical Director of the USC Thyroid Center and is recognized as a clinical expert in thyroid nodule management, thyroid cancer, as well as the spectrum of thyroid hormone dysfunction. He performs thyroid nodule evaluation and fine-needle aspiration biopsy at offices at Keck Hospital of USC and Pasadena.
After finishing his clinical and research training at the Keck School of Medicine and the Los Angeles County-USC Medical Center, Dr. Angell was appointed instructor in medicine at the Brigham and Women’s Hospital and Harvard Medical School in performing patient care, teaching, and research. In 2018, Dr. Angell joined the faculty at the Keck School of Medicine.
His clinical and research interests are related to the diagnosis and treatment of thyroid diseases. He has been nationally known for research into thyroid nodule evaluation and molecular testing of thyroid nodules. He has received funding for his research predicting thyroid cancer in patients with thyroid nodules from the Thyroid Cancer Survivors' Association (American Thyroid Association Research Grant). He has published articles in JAMA Surgery, Thyroid, The Journal of Clinical Endocrinology and Metabolism, and others, including original research and invited reviews. He is on the editorial board of Thyroid, VideoEndocrinology, and Frontiers in Endocrinology.
sc ctsi logoPowered by SC CTSI